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Abstract 1 
A transfection assay in a lymphoblastoid cell line infected with Epstein-Barr virus 2 
was used to compare the ability of type 1 and type 2 EBNA2 to sustain cell 3 
proliferation.  The reduced proliferation in cells expressing type 2 EBNA2 correlated 4 
with loss of expression of some cell genes that are known to be targets of type 1 5 
EBNA2.  Microarray analysis of EBNA2 target genes identified a small number of 6 
genes that are more strongly induced by type 1 than type 2 EBNA2 and one of these 7 
genes (CXCR7) was shown to be required for proliferation of lymphoblastoid cell 8 
lines. The Epstein-Barr virus LMP1 gene was also more strongly induced by type 1 9 
EBNA2 than type 2 but this effect was transient. Type 1 and type 2 EBNA2 were 10 
equally effective at arresting cell proliferation of Burkitt’s lymphoma cell lines 11 
lacking Epstein-Barr virus and were also shown to cause apoptosis in these cells. The 12 
results indicate that differential gene regulation by Epstein-Barr virus type 1 and type 13 
2 EBNA2 may be the basis for  the much weaker B cell transformation activity of 14 
type 2 Epstein-Barr virus strains compared to type 1 strains.  15 
 16 
Introduction 17 
Epstein-Barr virus (EBV) infects human B cells, giving rise in cell culture to 18 
lymphoblastoid cell lines (LCLs) in which the latent viral genome is maintained. In 19 
this infection, known as Latency III (33), all the EBNA and LMP viral proteins are 20 
expressed together with various non-coding small RNAs (EBER and miRNAs). The 21 
EBV genes expressed in latency III cause the proliferation and survival of the LCL 22 
cells (49). In latency III,  EBNA2 acts as a transcription factor to induce expression of 23 
the viral LMP genes and many cell genes (25). EBNA2 is known to be required for 24 
the continued proliferation of LCLs because an LCL (EREB2.5) engineered to 25 
 3
express an estrogen receptor EBNA2 fusion protein in the absence of wild type 1 
EBNA2 was dependent on estrogen for EBNA2 function and cell proliferation (24).  2 
In the tumour cells of the EBV associated cancer Burkitt’s lymphoma (BL), where 3 
EBV infection is described as latency I (33), EBNA2 is not expressed, proliferation 4 
being caused primarily by the de-regulation of c-MYC caused by a chromosome 5 
translocation characteristic of BL (7). Some BL cells in culture adapt to acquire a 6 
latency III pattern similar to that found in LCLs but the Akata BL cell line retains 7 
latency I EBV gene expression in culture.  8 
 9 
Natural sequence variation of EBV isolates has been described at many locations in 10 
the genome (3, 11, 12, 50) but the most prominent and biologically significant of 11 
these identified so far is the variation in EBNA2. EBV strains are classified as type 1 12 
or 2 (also known as type A and B) according to the sequence of their EBNA2 gene 13 
(25). The protein sequences of type 1 and type 2 EBNA2 are only 55% identical, a 14 
remarkable difference in view of the very low degree of variation in most other genes 15 
in the EBV genome. Type 1 strains are found worldwide and efficiently immortalise 16 
human B cells to give LCLs but type 2 strains are much less effective at producing 17 
LCLs (32). Type 2 EBV strains are almost equally abundant as type 1 strains in Africa 18 
and some other regions of the world but are much less frequent than type 1 in Europe 19 
and the USA.   A recombinant EBV type 2 strain in which the EBNA2 coding 20 
sequences were replaced with type 1 EBNA2 acquired the efficient immortalisation of 21 
B cells  characteristic of type 1 EBV (9), showing that EBNA2 variation is the key 22 
difference, although additional variation in EBNA3 family genes and EBNA-LP 23 
linked to type 1 and type 2 has been described (29, 34).  24 
 25 
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The mechanism by which type 1 EBNA2 acts as a transcription factor has been 1 
studied in detail. EBNA2 contains a transcription activation domain but does not bind 2 
directly to DNA, instead binding to certain cell proteins that mediate the DNA 3 
binding in promoter regions (25). The most studied of these proteins is RBP-Jk 4 
(CBF1) but the cell transcription factors PU.1 and AP2 can also mediate its effects on 5 
some promoters. The LMP2A gene is a clear example of a promoter that is regulated 6 
by EBNA2 via RBP-Jk (52). In contrast, PU.1 and AP2 are also important for 7 
regulation of the promoter for LMP1 by EBNA2 (18, 19, 22, 27, 35, 36). In addition, 8 
EBNA2 can modify chromatin structure through recruitment of SWI/SNF (46-48). 9 
Although there has been extensive investigation of the mechanism of EBNA2 10 
induction on transfected model promoters and reporter plasmids, the relative 11 
significance of the SWI/SNF complex activity and transcription activator/repressor 12 
recruitment on promoters at their natural locations in human chromosomes remains to 13 
be determined.  14 
 15 
The sequences of type 1 and type 2 EBNA2 are quite similar in the parts of the 16 
proteins known to mediate binding to RBP-Jk and in the activation domain; the main 17 
sequence variation occurs elsewhere in the protein. Almost all published studies of 18 
EBNA2 mechanism have used type 1 EBNA2 but the ability of type1 and type 2 19 
EBNA2 to induce gene expression has been compared on the promoters for LMP1 20 
(43, 44) and CD23 (43). 21 
 22 
In addition to the EBV LMP promoters and the Cp EBNA promoter, EBNA2 23 
regulates many genes in the human genome. These EBNA2 target genes were initially 24 
studied individually but several recent microarray studies have identified large 25 
 5
numbers of genes regulated by EBNA2 type 1. Various approaches to identification of 1 
EBNA2 target genes have been described, using either LCLs with conditionally active 2 
EBNA2 (37, 51) or the effect of conditionally active EBNA2 in EBV negative BL cell 3 
lines (28).  In our study (37) we sought to identify direct targets of EBNA2 regulation 4 
in the EREB2.5 LCL by inducing EBNA2 function in the presence of protein 5 
synthesis inhibitors. RNAs that were induced were considered to be directly regulated 6 
by EBNA2 in the sense that their induction did not depend on protein synthesis of 7 
intermediate genes. We have investigated the roles of some of these EBNA2 targets in 8 
detail, for example RUNX3 and PI3 kinase p55α (37, 38). 9 
 10 
In contrast to LCLs where EBNA2 induces c-MYC, in latency I or EBV negative BL 11 
cells EBNA2 down regulates expression of the translocated c-MYC allele and causes 12 
cell cycle arrest (21). Although type 2 EBNA2 is relatively frequent in Africa and 13 
many BL cell lines contain type 2 EBV, only type 1 EBNA2 has so far been analysed 14 
in the context of c-MYC regulation in BL cells. In this paper we investigate functional 15 
differences between type 1 and type 2 EBNA2, studying the effects of physiologically 16 
normal levels of EBNA2 or ER-EBNA2 protein on regulation of cell genes and the 17 
EBV LMP1 gene. A previous report (9) showed approximately equal expression of 18 
LMP1 in comparable LCL cells expressing type 1 or type 2 EBNA2. We confirm this 19 
but reveal a different time response of LMP1 expression and identify several cell 20 
genes that are differentially regulated by type 1 and type 2 EBNA2, including a gene 21 
required for LCL proliferation. The results suggest mechanisms that might explain the 22 
different abilities of type 1 and type 2 EBV to convert B cells into LCLs. 23 
 24 
 6
Materials and Methods 1 
EBNA2 plasmids  2 
For clarity in this paper, the name  pER-EBNA2 T1 will be used for p554-4 (24) and 3 
pEBNA2 T1 will be used for p554 (24); both plasmids were kindly provided by B. 4 
Kempkes. Analogous plasmids were constructed containing type 2 EBNA2. For 5 
construction of pER-EBNA2 T2 (also known as pERT2), EBNA2 type 2 was 6 
amplified by Pfu PCR from genomic DNA extracted from AG876  cells. The 7 
amplified product was cloned and sequenced to verify its identity to the published 8 
AG876 EBNA2 sequence (10, 12). Adaptors included in the PCR primers allowed 9 
substitution of the ER-EBNA2 sequence in pER-EBNA2 T1 with ER-EBNA2 T2.  A 10 
similar strategy was used to clone pEBNA2 T2 (also known as pAG1) using the same 11 
AG876 EBNA2 DNA to substitute the EBNA2 sequence of pEBNA2 T1.   12 
 13 
To make plasmids for in vitro translation of type 1 or type 2 EBNA2, EBNA2 14 
sequences were Pfu PCR amplified from pER-EBNA2 T1 or T2  using primers with 15 
overhanging sequences carrying XbaI (5') and EcoRI (3') restriction sites. The 16 
amplified products were cloned into pSP64 (Promega). In vitro transcription and 17 
translation was performed using the TnT reticulocyte lysate system (Promega) with 18 
SP6 polymerase, using 1µg of template vector and 2µl of 10mCi/ml 35S-methionine, 19 
in a 50 µl final reaction. Dilutions of the type 1 and type 2 in vitro translations were 20 
run on SDS-PAGE, blotted and the filter exposed on a phosphorimager. The same 21 
filter was then used for immunoblotting with PE2 antibody and the EBNA2 detected 22 
by ECL. Type 1 EBNA2 contains 10 Met residues and type 2 has 9: the images were 23 
compared using ImageQuant 5.0 software.  24 
 25 
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Cell culture  1 
BL cell lines and the LCL EREB2.5 (24) were grown at 37o in RPMI 1640 with 10% 2 
fetal calf serum and 50 units/ml penicillin/streptomycin. For EREB2.5 cells, RPMI 3 
1640 medium lacking phenol red but containing 1μM β-estradiol was used. 293 cells 4 
were grown in DMEM with 10% fetal calf serum and penicillin/streptomycin. 5 
 6 
For estrogen starvation and induction of EREB2.5 cells (Fig 4A), the cells were 7 
washed twice in unsupplemented RPMI and resuspended at 5x105 cells/ml in medium 8 
without estrogen. After 4 days, cells were counted again and reincubated in fresh 9 
medium without estrogen. On the fifth day, protein synthesis inhibitors (50μg/ml 10 
cycloheximide and 25μg/ml anisomycin) were added if required (Fig 4A, middle 11 
panels) prior to addition of 1μM estrogen or ethanol as a solvent control. The 12 
induction with estrogen was continued for 4 hours in the 37°C incubator. Cells were 13 
harvested by washing twice in unsupplemented medium before protein extraction. 14 
 15 
Transfection, 3H-thymidine labelling and RNAi  16 
For Amaxa transfection of EREB2.5 cells, 5x106 cells growing in medium with 17 
estrogen were collected by centrifugation and resuspended in 100 μl of supplemented 18 
solution T (Amaxa Biosystems) at room temperature. 5 µg of plasmid DNA was 19 
added and the mixture was transferred to an Amaxa cuvette and nucleofected using 20 
Amaxa program A-23. 500μl of warmed medium was then added to the cuvette and 21 
cells were transferred to 6 ml of warmed medium.  Estrogen was omitted from the 22 
culture medium after transfection for the experiments shown in Fig 1 and 4C. 23 
 24 
 8
For 3H-thymidine labelling, cells suspended in 200 µl medium were aliquoted into 1 
wells of 96 well plates and incubated for 2 hours at 37ºC in the presence of 1µCi of 2 
3H-thymidine. Cells were  harvested on to filters using a cell harvester (Skatron) and 3 
radioactivity was measured in a scintillation counter. 4 
 5 
EBV negative Akata 31 BL (AK31) cells (20) expressing a conditional EBNA2 type 1 6 
or type 2 were obtained by first electroporating 5x106 cells with 5 µg of puro-oriP-7 
EBNA1 vector (2) using a BioRad electroporator set at 960µF and 250V. 1 μg/ml 8 
puromycin was added 24 hours after transfection. The selected AK31 cell line 9 
expressing EBNA1 was grown out, characterized and then transfected with pER-10 
EBNA2 T1 or pER-EBNA2 T2 vector using the same electroporation conditions. 1 11 
mg/ml G418 was added 24 hours post transfection and selection was carried on in 12 
G418 and puromycin for about 4 weeks, by which time cells expressing EBNA1 and 13 
ER-EBNA2 had grown out. Daudi BL cells were transfected with pER-EBNA2 T1 or 14 
pER-EBNA2 T2 under the same electroporation conditions, and selected with 400 15 
µg/ml G418.  16 
 17 
293 cells were transfected using lipofectamine complexes formed by mixing 50 µl of 18 
serum free medium containing 8 µg of plasmid DNA with 50 µl of serum free 19 
medium containing 10 µl of lipofectamine and incubating for 20 minutes at room 20 
temperature. The complexes were added to 6x106 cells at 90% confluence and 21 
incubated for 24 hours at 37ºC before replacing the medium  and adding 1μg/ml 22 
puromycin. Cells were passaged as required to avoid confluence and counted after 8 23 
days. 24 
 25 
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For shRNA RNAi of CXCR7, oligonucleotides 1 
GATCCCCAGCAAAGTAGCTTCGGGTCTTCAAGAGAGACCCGAAGCTACTT2 
TGCTTTTTTGGAAA and 3 
AGCTTTTCCAAAAAAGCAAAGTAGCTTCGGGTCTCTCTTGAAGACCCGAA4 
GCTACTTTGCTGGG  were cloned into puro-oriP-SUPER, a puromycin resistant 5 
version of the pHEBo-SUPER plasmid described previously (38) and plasmid DNA 6 
was Amaxa electroporated into EREB2.5 cells. Transfected cells were grown in 7 
1μg/ml puromycin and viable cell numbers were determined at the indicated time 8 
points later. Samples were taken on day 7 for RT-PCR analysis.  9 
 10 
RNA extraction and RT-PCR 11 
Total cell RNA was extracted using Trizol and cDNA was prepared using the 12 
Protoscript first strand cDNA synthesis kit (New England Biolabs). Before reverse 13 
transcription, RNA samples were treated with RQ1 RNasefree DNase (Promega). 14 
CXCR7 PCR used the following primers:  15 
Splice 1 Fw: CAGCTTCAGATCTGGGTATTTATCC  16 
Splice 2 Fw; GCAGCCAGCAGAGCTCACAGTTG  17 
Splice 1/2 rev: TGGGCATGTTGGGACACATCACC 18 
GAPDH was amplified with primers TGCCTCCTGCACCACCAACT and 19 
CGCCTGCTTCACCACCTTC.  20 
ADAMDEC1 was amplified with primers CTCTCCCTACAAAAAACCAAGCAC 21 
and TGTGTGAAGTATCCTCTCAACCCG. 22 
Microarray analysis 23 
Microarray analysis was performed on Agilent G4112F 44K HD arrays (design ID  24 
014850) exactly as recommended by the manufacturer (Two-Color Microarray-Based 25 
 10
Gene Expression Analysis V5.0.1, Agilent Technologies). Data extraction was 1 
performed with feature extraction software V9.1.3.1 by using the protocol file “GE2-2 
v5_91_0806.xml”. AK31:EBNA1/ER-EBNA2 type 1 or type 2 cells were pre-treated 3 
for 1hr with protein synthesis inhibitors, then with or without estrogen for 4 hrs in the 4 
presence of protein synthesis inhibitors. Total cell RNA was extracted and used for 5 
expression profiling. The experiment was performed in duplicate and the resulting 6 
RNAs were hybridised pairwise (estrogen-treated versus control) on four individual 7 
microarrays. The geometric mean of the four ratios/probe across all arrays was 8 
calculated. The output files from the Agilent Feature Extraction software for each 9 
microarray include the signal (MedianSignal), standard deviation of the signal 10 
(PixSDev), background (BGMedianSignal) and corrected signal (ProcessedSignal; dye-11 
normalized signal after surrogate algorithm, used for computation of log ratio) for each 12 
channel (Cy3 and Cy5). From these, a signal to noise (S/N) ratio for each channel (= 13 
signal/background) and relative error (= SD signal/signal) were calculated. Analyses 14 
were done with the log ratio calculated from the corrected signals (Cy3 and Cy5). To 15 
describe the quality of the ratio value the smaller of the two S/N values was used while 16 
for the relative error the higher one was selected. The microarray data analysis was 17 
performed using the software Genedata Expressionist® Pro (Genedata AG, Basel, 18 
Switzerland). 19 
Immunoblotting and ELISA 20 
SDS gel electrophoresis and Western immunoblotting was performed as described 21 
previously (38).  Antibodies and dilutions used were EBNA2,  DAKO PE2 mouse 22 
monoclonal (1/500); LMP1,  DAKO CS1-4 mouse monoclonal (1/500); IRF4, AB-23 
cam ab27508 rabbit polyclonal (1/1000); IL-1β: ABcam ab10749 mouse monoclonal 24 
(1/200); Actin: Abcam AC-15 (1/20000); Cell Signalling Technologies anti-cleaved 25 
 11
human PARP  Asp214: (1/1000); cMYC: Abcam 9E-10 mouse monoclonal (1/500). 1 
Secondary antibodies were HRP conjugated anti-mouse or anti-rabbit at 1/2000 and 2 
detection was by ECL (GE Healthcare).  3 
 4 
ELISA for IL-1β used the Quantikine DLB50 kit (R&D systems). AK31:EBNA1/ER-5 
EBNA2 T1 or T2 cells were treated with estrogen for 24 hours or kept untreated as 6 
controls and then protein was extracted in 200 μl CAT-ELISA buffer. The extract was 7 
added to the ELISA plate provided in the kit and incubated for 2 hours. The plate was 8 
washed 3 times then incubated for 1hr with secondary antibody, washed three times 9 
and developed, following the instructions with the kit. 10 
 11 
Analysis of DNA content by Propidium Iodide staining 12 
Cell were harvested and fixed in 70% ethanol in PBS overnight at 4 °C. Fixed cells 13 
were washed three times in 1ml cold PBS, then resuspended in 500 μl 50μg/ml 14 
propidium iodide (PI) in PBS containing RNaseA (0.5mg/ml) and incubated for 30 15 
minutes at 37 °C prior to analysis. PI-stained cells were then analysed for DNA 16 
content by flow cytometry.    17 
 18 
Apoptosis assays  19 
For the JC-1 assay, cells were cultured at a density of 1 x 106 cells/ml in medium 20 
containing 2 μM JC-1 (Molecular Probes, Invitrogen) for 30 minutes at 37 °C, 5% 21 
CO2. Positive control samples were also incubated with 50 μM membrane potential 22 
disrupter CCCP (Molecular Probes, Invitrogen) to uncouple mitochondria. After the 23 
incubation period, cells were washed in 2 ml warm PBS and resuspended in 500 μl 24 
PBS for analysis by flow cytometry. 25 
 12
  1 
To measure DNA laddering, cells were harvested after treatment and DNA was 2 
extracted as described (15). The extent of DNA fragmentation was visualised on a 1% 3 
agarose gel containing Ethidium Bromide.   4 
 5 
Results 6 
Assay for EBNA2 function distinguishes type 1 from type 2 7 
Transfection of an oriP plasmid expressing wild-type type 1 EBNA2 into EREB2.5 8 
cells was previously demonstrated to allow continued growth of the cells in the 9 
absence of estrogen. EBNA2 is known to be essential for the growth of LCLs and the 10 
wild type EBNA2 takes over from the ER-EBNA2, the episomal ER-EBNA2 plasmid 11 
eventually being lost from the cells (16, 24, 37). This procedure was adapted into an 12 
assay that functionally distinguishes type 1 from type 2 EBNA2. The type 1 EBNA2 13 
sequences in the EBNA2 T1 expression plasmid (24) were replaced with type 2 14 
EBNA2 coding sequence. The type 1 or type 2 EBNA2 plasmids were then 15 
transfected into EREB2.5 cells that had been growing normally with estrogen and 16 
estrogen was removed from the culture. Monitoring DNA synthesis by 3H thymidine 17 
incorporation gave the expected continued DNA synthesis with type 1 EBNA2 but 18 
with type 2 EBNA2 there was only a brief period of DNA synthesis before 19 
incorporation of 3H thymidine declined and cell proliferation ceased (Fig 1A). A 20 
negative control transfection in which a plasmid expressing no EBNA2 was 21 
transfected gave no significant  3H thymidine incorporation. Such transfections 22 
eventually resulted in outgrowth in the absence of estrogen of typical LCLs with type 23 
1 EBNA2 (Fig 1B). These cells expressed EBNA2 and after 3 months in culture had 24 
almost completely lost expression of the ER-EBNA2 fusion protein, as detected by 25 
 13
western blotting (Fig 1B), presumably because of passive loss of the ER-EBNA2 1 
plasmid from the cells. The plasmids encoding type 1 and type 2 differed only in the 2 
EBNA2 coding region and expressed similar levels of EBNA2 protein at early times 3 
after transfection (3 days), as detected by Western blotting  with the PE2 monoclonal 4 
antibody (Fig 1C). To check that the PE2 monoclonal antibody detects type 1 and 5 
type 2 EBNA2 with equal efficiency on a western blot, EBNA2 was prepared by in 6 
vitro translation incorporating 35S methionine. Dilutions of the samples were analysed 7 
by western blotting with PE2 and a phosphorimager was used to measure 35S Met 8 
incorporation on the same gel. The results (Fig 1D) showed that PE2 detected type 1 9 
and type 2 EBNA2 with approximately equal efficiency in the western blotting assay. 10 
 11 
In Figure 1A, the key point of difference in the time course of 3H thymidine 12 
incorporation was about 3 to 4  days after transfection,  when incorporation in the type 13 
1 transfection was still increasing strongly as the cells proliferated but the culture with 14 
type 2 EBNA2 was stopping DNA synthesis. EBNA2 regulates expression of the viral 15 
LMP1 protein and LMP1 signal transduction is an important factor in proliferation 16 
and survival of EBV LCLs but it was noticeable that the level of LMP1 3 or 4 days 17 
after transfection and estrogen withdrawal was similar in the western blotting samples 18 
from the type 1 and type 2  transfections. In contrast, there were major differences in 19 
the expression level of some cell genes identified previously as EBNA2 targets, for 20 
example RUNX3 and IRF4 (Fig 1C).  We showed previously that RUNX3 is required 21 
for proliferation of  EREB2.5 LCLs (38) so this experiment indicates that differential 22 
expression of a cell gene that is directly controlled by EBNA2 correlates with the 23 
different proliferative capacity of type 1 and type 2 EBNA2.  24 
 25 
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Identification of cell genes differentially regulated by type 1 and type 2 EBNA2 1 
Our previous strategy for identification of direct target genes of type 1 EBNA2 in the 2 
EREB2.5 LCL background (37) can not be applied to type 2 EBNA2 because the ER-3 
EBNA2 (type 2) does not sustain cell proliferation. There were many similarities in 4 
the lists of EBNA2 target genes identified by our approach and that of EBNA2 5 
expression in an EBV negative Burkitt’s lymphoma cell line (28) so we therefore 6 
created EBV negative Akata (AK31) BL cell lines with constitutive expression of 7 
type 1 or type 2 ER-EBNA2.  The ER-EBNA2 was expressed from episomal oriP 8 
vectors selected with G418 and the EBNA1 required for this plasmid maintenance 9 
was provided from another oriP plasmid in the cells under  puromycin selection.  10 
There was characteristically some stabilisation of the EBNA2 protein when the cells 11 
were treated with estrogen (Fig 2), as is seen also in EREB2.5 cells. The 12 
AK31:EBNA1/ER-EBNA2 cell lines were treated with estrogen in the presence of 13 
protein synthesis inhibitors for 4 hours and total cell RNA was analysed by 14 
microarray expression profiling. Levels of cell RNAs were compared in response to 15 
type 1 or type 2 EBNA2 activation. Most cell genes are not regulated by EBNA2 16 
activation but based on the filter criteria applied, approximately 150 genes were 17 
induced two fold or more, consistent with previous studies (28, 37, 51). Examples of 18 
these genes that were also classified as direct targets of EBNA2 regulation in 19 
EREB2.5 cells in our previous analysis (37) are shown in Fig 2. For most of these, 20 
there was no detectable difference in regulation by type 1 or type 2 EBNA2 but for a 21 
few genes there was significantly more induction by type 1 EBNA2. The genes 22 
regulated differentially in Fig 2 included MARCKS, IL1β, ADAMDEC1 and CXCR7 23 
(also known as RDC1, CMKOR1). The induction of mRNA expression for these 24 
genes was about 3 fold higher with type 1 EBNA2.  25 
 15
 1 
Induction of IL1β was confirmed at the protein level in AK31:EBNA1/ER-EBNA2 2 
(type 1) cells in response to estrogen activation of the EBNA2, both by ELISA assay 3 
(Fig 3A) and Western blotting (Fig 3B), but this protein was intracellular and could 4 
not be detected in the culture medium.  RT-PCR for ADAMDEC1 confirmed its 5 
induction (Fig 3C) and MARCKS has been reported previously to be induced by EBV 6 
infection of BL cells (6).  Interestingly, CXCR7 was the RNA most strongly induced 7 
by EBNA2 type 1 in our previous study on direct EBNA2 targets in EREB2.5 LCLs 8 
(37) and was also found to be strongly induced in the EBV negative BL cell 9 
background in other studies (28).  10 
 11 
Induction of CXCR7 was confirmed by RT-PCR  both in the AK31:EBNA1/ER-12 
EBNA2 T1 cells and in EREB2.5 cells in response to estrogen activation of the 13 
EBNA2 (Fig 4A). Two known splice variants in the leader exons of CXCR7 and a 14 
novel splice of exon 2 directly to the coding exon were observed in the RT-PCR 15 
assays (Fig 4A). The differential regulation of CXCR7 and ADAMDEC1 by type 1 16 
and type 2 EBNA2 observed in the BL cell lines (Fig 2) was also seen in EREB2.5 17 
cells transfected with EBNA2 expression vectors followed by withdrawal of estrogen 18 
(Fig 4B), similar to the experiment shown in Fig 1. The time course of the experiment 19 
in Fig 4B was slightly slower than that shown in Fig 1 and the differential regulation 20 
of CXCR7 and ADAMDEC1 by type 1 and type 2 EBNA2 was most clearly seen 7 21 
and 10 days after transfection, relative to a GAPDH control (Fig 4B).  EREB2.5 cells 22 
were not unusual in expressing CXCR7; a similar pattern of expression was observed 23 
in a  panel of LCLs (Fig 4C). These LCLs were derived from cord blood (C2-BL16, 24 
C2-Akata, IB4, EREB2.5) or peripheral blood (LCL3, Obaji LCL) B cells and 25 
 16
contained several different EBV strains (LCL3 contains B95-8 EBV).  C2-BL16 1 
contains a type 2 EBV but has a similar level of CXCR7 RNA to the other lines, 2 
suggesting that once an LCL has been established, cells with this level of CXCR7 3 
may be selected, if CXCR7 is required for LCL proliferation or survival.  4 
 5 
Using a similar shRNA plasmid transfection approach to that we applied previously to 6 
test the contribution of RUNX3 and p55α PI3kinase to LCLs (37, 38), we 7 
investigated the effect of depleting CXCR7. Knockdown of CXCR7, detected at the 8 
RNA level (Fig 5A, B), resulted in a severe impairment of accumulation of 9 
transfected EREB2.5 cells (Fig 5A) or LCL3 cells (Fig 5B) and cell death. In those 10 
experiments p53 RNAi and the empty vector were used as negative controls (37, 38) 11 
and affected neither the levels of CXCR7 RNA nor accumulation of the cells in 12 
culture.  The shRNA plasmids were also transfected into 293 cells and puromycin 13 
selection was applied (Fig 5C). There was no difference between the  CXCR7 and 14 
empty vector shRNA plasmids in the production of puromycin resistant 293 cells, 15 
indicating that the CXCR7 shRNA construct was not non-specifically toxic and did 16 
not prevent function of the puromycin resistance gene used in Fig 5A, B.  17 
 18 
These results show that some cell genes (including CXCR7) can be differentially 19 
regulated by type 1 and type 2 EBNA2 and a CXCR7 gene product is required for 20 
LCL proliferation or survival. 21 
 22 
 23 
 24 
 25 
 17
Type 1 and type 2 EBNA2 both cause cell cycle arrest and apoptosis in EBV 1 
negative BL cell lines expressing EBNA1 2 
In the experiment shown in Fig 2C, the effects of EBNA2 on cell gene expression 3 
were measured only 4 hours after activation of the ER-EBNA2 by estrogen. Earlier 4 
work has shown that there appears to be an incompatibility between EBNA2 5 
expression and latency I BL cells that results in selection of tumour cells lacking 6 
EBNA2 expression (23). One potential mechanism for this is the ability of type 1 7 
EBNA2 to down regulate the expression of the translocated c-Myc allele in BL cells 8 
and consequently cause cell cycle arrest (21).  Many African BL tumours contain type 9 
2 EBV so we therefore compared the effects of type 1 and type 2 ER-EBNA2 on 10 
AK31 BL cells over a longer time period. Both type 1 and type 2 ER-EBNA2 11 
suppressed c-MYC protein levels (Fig 6A) and caused the previously described (21) 12 
accumulation of cells in the G1 phase of the cell cycle after about 24 hours (Fig 6B).  13 
In addition to the previously reported cell cycle arrest (21), these BL cells 14 
subsequently died by apoptosis in response to EBNA2 expression. The accumulation 15 
of cleaved PARP (Fig 6B), sub-diploid DNA content on FACS (Fig 6B), JC-1 assay 16 
(Fig 6C) and DNA laddering (Fig 6D) all confirmed the apoptotic mechanism of cell 17 
death.  Similar effects of accumulation in G1 and subsequent apoptosis were also 18 
observed in DG75 EBV negative BL cells containing the same ER-EBNA2 plasmids 19 
(data not shown)  Both type 1 and type 2 EBNA2 caused all these effects but in some 20 
experiments the PARP cleavage in response to type 2 EBNA2 was slightly slower 21 
(Fig 6A).  22 
 18
 1 
Differential regulation of LMP1 by type 1 and type 2 EBNA2 2 
A previous report compared the levels of LMP1 in LCLs stably expressing type 1 or 3 
type 2 EBNA2 and found them to be similar (9).  We transfected the ER-EBNA2 4 
(type 1 and type 2) plasmids into Daudi BL cells, which contain an endogenous EBV 5 
genome with a deletion of the EBNA2 gene, and selected transfected cell lines with 6 
G418. Because LMP1 is normally induced by EBNA2, LMP1 protein is not usually 7 
present in Daudi cells at a significant level. When EBNA2 function was induced by 8 
adding estrogen, type 1 EBNA2 induced LMP1 much more rapidly than type 2 9 
EBNA2 (Fig 7), even though the expression of type 2 EBNA2 was slightly stronger 10 
(Fig 7).  This difference in LMP1 induction was large but transient; after 48 hours 11 
there was little difference in the levels of LMP1, consistent with the previously 12 
published result in cells stably expressing type 1 or type 2 EBNA2  (9). In contrast to 13 
the EREB2.5 cells (Fig 1), where the continued expression of LMP1 was measured 14 
following transfection of EBNA2, this Daudi cell system measures the effect of 15 
EBNA2 activation in cells that start with no LMP1 expression, more like the 16 
induction of LMP1 during infection of primary B cells by EBV. 17 
 18 
Discussion 19 
The important biological difference between type 1 and type 2 EBV strains is the 20 
much greater ability of type 1 strains to convert primary human B cells into 21 
continuously proliferating LCLs (9, 32). The systems we have devised allow study of 22 
gene regulation by EBNA2 at physiological levels on target genes in their normal 23 
regulatory context.  The results suggest several possible reasons why type 1 EBV 24 
strains may produce LCLs more efficiently than type 2 strains. Timely induction of 25 
 19
LMP1 is important to allow survival of B cells driven into the cell cycle by EBNA2 1 
and EBNA-LP and our results in Daudi cells suggest that type 1 EBNA2 induces 2 
LMP1 much more rapidly and efficiently than type 2 EBNA2.  3 
 4 
Previous studies comparing the ability of type1 and type 2 EBNA2 to induce gene 5 
expression focussed on LMP1 (43, 44) and CD23 (43).  Transient transfection assays 6 
of EBNA2 expression vectors into BL30/P3HR1 or Daudi cells assayed by 7 
immunoprecipitation of LMP1 gave a higher induction by type 2 EBNA2 in some 8 
experiments but equal induction in others (44).  In contrast, transient transfection 9 
assays in BJAB cells gave about a 2.5 fold higher induction of an LMP1 promoter 10 
CAT reporter with type 1 EBNA2 and about a 1.5 fold higher induction of a CD23 11 
promoter CAT construct (43).  These results were interpreted to suggest that higher 12 
transactivation by type 1 EBNA2 might be the basis for the more efficient 13 
transforming properties of type 1 EBV. At that time the cooperation of EBNA2  with 14 
EBNA-LP was not taken into account.  15 
 16 
All our experiments have been performed in the presence of the 2 repeat type 1 17 
EBNA-LP that is expressed from p554 series plasmids (24).  There is some evidence 18 
that type 1 and type 2 EBNA-LP can differ in their ability to cooperate with EBNA2 19 
(29) in induction of the LMP1 promoter and that EBV sequence variation in the 20 
LMP1 promoter (studied in P3HR1 EBV) can cause it to respond to type 1 EBNA2 21 
slightly differently from the prototypic B95-8 LMP1 promoter (18). In some respects 22 
it is surprising that we observed no outgrowth with type 2 EBNA2 in the EREB2.5 23 
complementation assay since type 2 strains of EBV usually give rise to a low 24 
efficiency transformation of primary B cells. It is possible that the 2 repeat type 1 25 
 20
EBNA-LP expressed from both the type 1 and type 2 EBNA2 expression vectors used 1 
in this paper cooperates more effectively with the type 1 EBNA2 than the type 2 2 
EBNA2 but there is no specific evidence for this. The EBNA-LP activity in the 3 
EREB2.5 cells is further complicated by the presence of the P3HR1 truncated EBNA-4 
LP, which has recently been reported to be a gain of function mutant, acquiring the 5 
ability to inactivate protein phosphatase 2A (13). These additional levels of 6 
complexity have not yet been explored in our study but they do not affect our 7 
conclusion that there can be differential regulation of a relatively small number of cell 8 
genes by type 1 and type 2 EBNA2.  9 
 10 
The Akata cell line used for the microarray analysis and apoptosis studies in this 11 
paper has an 8:14 translocation (41) similar to the BL cell lines studied previously 12 
(21) so the repression of c-MYC by EBNA2 shown in Fig 6 presumably occurs by the 13 
same mechanism involving the Ig Mu enhancer. In the Akata cells, type 1 and type 2 14 
EBNA2 appeared to be equally effective in repressing c-MYC so there is no reason to 15 
think that the differential regulation of cell target genes we observed is mediated by c-16 
MYC. The protein synthesis inhibitors present in the microarray study would also 17 
most likely prevent indirect effects that could occur via c-MYC. The mechanism by 18 
which apoptosis occurs in the Akata BL cells after cell cycle arrest (Fig 6) remains to 19 
be determined but the similar effects of type 1 and type 2 EBNA2 in BL cells are 20 
consistent with both EBV types being found in African BL tumours.  21 
 22 
The experiments illustrated in Fig 1 in the EREB2.5 LCL involved Amaxa transient 23 
transfection and could only be performed on a small scale so it was only possible to 24 
test a few EBNA2 target genes by Western blotting (Fig 1C) or RT-PCR (Fig 4B). It 25 
 21
is noticeable that RUNX3, which is known to be required for LCL proliferation (38) 1 
and was differentially expressed in the LCL experiment (Fig 1C), was not in the list of 2 
differentially regulated target genes in the Akata BL system (Fig 2). Although 3 
RUNX3 was confirmed as an EBNA2 target gene in BL cells (28), it was only 4 
slightly induced in those experiments and it seems likely that differences in the 5 
transcription factor content in the different cell backgrounds will affect which genes 6 
are detected as EBNA2 targets, as will the different experimental procedures used. 7 
However, the biochemical functions of the four genes identified in Figure 2, namely 8 
MARCKS, IL1βADAMDEC1 and CXCR7, are likely to be relevant to B cell 9 
proliferation and survival. ADAMDEC1 and CXCR7 were also shown to be 10 
differentially regulated by type 1 and type 2 EBNA2 in the LCL background (Fig 4B). 11 
 12 
MARCKS (myristoylated alanine-rich protein kinase C substrate) is a PKC substrate 13 
and its phosphorylation has been used as a marker of PKC activation (1). It regulates 14 
membrane ruffling and cell spreading (30) and can reversibly inhibit phospholipase C 15 
(14) Targeted disruption of the gene encoding MARCKS in mice resulted in 16 
numerous developmental defects and perinatal death (40). MARCKS was previously 17 
shown to be induced by EBV infection (6) although in our experiments the induced 18 
level of MARCKS RNA was still very low so it is probably also regulated by another 19 
EBV gene product apart from EBNA2.  IL1β is a cytokine involved in lymphocyte 20 
proliferation and has been reported previously to be expressed in EBV infected LCLs 21 
(26). Its function normally requires that it is secreted so that it can activate via its 22 
specific receptor but intracellular IL1β protein similar to that seen in our BL studies 23 
has been studied previously as an inhibitor of caspase activation (42) and intracellular 24 
IL-1α precursor form has been reported to function as a transcription regulator (8, 45) 25 
 22
so this intracellular IL-1β might be functional. ADAMDEC1 is a metalloprotease that 1 
is expressed in lymphocytes,  dendritic cells and macrophages (5). Its precise function 2 
is not yet known but its expression has been used as a marker to distinguish splenic 3 
from peritoneal B cells of the B-1a class (39). 4 
 5 
CXCR7 (RDC1, CMKOR1) was recently found to be the receptor for chemokine 6 
SDF-1/CXCL12 in T lymphocytes (4) although there is doubt about this being the 7 
ligand for CXCR7 in B cells (17). The function of CXCR7 in normal B cells has not 8 
yet been determined but we demonstrated (Fig 4B) that it is required for LCL 9 
proliferation or survival and a previous study identified CXCR7  as essential for 10 
transformation of endothelial cells by Kaposi's sarcoma-associated herpesvirus (31). 11 
 12 
Further work will be required to characterize differential gene regulation by type 1 13 
and type 2 EBNA2 but there does appear to be a small number of cell genes that are 14 
more differentially regulated than the great majority of EBNA2 target genes.  We do 15 
not expect a single cell gene to complement the deficiency in type 2 EBV 16 
immortalization of B cells but it may be a relatively small number of genes that is 17 
required. The mechanism of the differential effects of type 1 and type 2 EBNA2 on 18 
these few genes remains to be determined but we conclude that differential induction 19 
of LMP1 and a relatively small number of cell genes correlates with the different 20 
transforming abilities of type 1 and type 2 EBV.   21 
 22 
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Figure legends 1 
Figure 1 2 
A. EREB2.5 cells, which had been growing normally in estrogen, were washed to 3 
remove estrogen and transfected with EBNA2 T1 or T2 vector expressing EBNA2 4 
type 1 or type 2 protein. Cells were cultured in the absence of estrogen and pulse 5 
labelled at the times indicated with 3H-Thymidine. 6 
B.  Phase contrast images of cells from Fig 1A 7 days after transfection of EBNA2 7 
plasmid showing proliferating cells only with type 1 EBNA2. Lower panel is a 8 
western blot for EBNA2 in 3 LCLs after 3 months of outgrowth. 9 
C.  Western blots of extracts from the same transfections assayed in part A 3 or 4 days 10 
after transfection as indicated for EBNA2, LMP1, IRF4, RUNX3 and actin as a 11 
loading control.  12 
D.  Comparison of detection of in vitro translated type 1 and type 2 EBNA2 by 13 
western blotting with PE2 antibody. Relative detection by Western blotting (WB) is 14 
similar to 35S Met labelling during the in vitro translation.  15 
 16 
Figure 2 17 
Bar chart summary of microarray expression profiling comparing genes regulated by 18 
ER-EBNA2 type 1 and type 2 stably transfected in AK31 BL cells. Cells were pre-19 
treated for 1hr with protein synthesis inhibitors, then with or without estrogen for 4 20 
hrs in the presence of protein synthesis inhibitors. Total cell RNA was extracted and 21 
used for expression profiling on Agilent 44K microarrays (as described in the 22 
methods section). The experiment was performed in duplicate and the resulting RNAs 23 
were hybridised pairwise (estrogen-treated versus control) on individual microarrays. 24 
For each condition the values were averaged and a standard error was calculated. 25 
 32
Each column represents the ratio of the mean of values plus estrogen over the mean of 1 
the values minus estrogen (fold induction).  The inset panel shows western blotting 2 
using PE2 antibody of ER-EBNA2 levels in the AK31:EBNA1/ER-EBNA2 cells with 3 
or without 4 hrs treatment with estrogen. 4 
 5 
Figure 3 6 
A.  ELISA detection of IL1β. AK31:EBNA1/ER-EBNA2 type 1 or type 2 cells were 7 
cultured with or without estrogen for 24 hrs. The medium and cell extracts (IC) were 8 
assayed for IL1β by ELISA. 9 
B. Cells were treated as in (A) and analysed by western blotting for  IL1β 10 
C. Cells were treated as in (A) and analysed by RT-PCR for ADAMDEC1 and 11 
GAPDH as a positive control. 12 
 13 
Figure 4 14 
A. Left panels: Estrogen starved EREB2.5 cells (E2.5) were treated with estrogen for 15 
4 hours and RNA was extracted and analysed by RT-PCR for CXCR7 mRNA using 16 
indicated primer combinations (right panels) to detect alternately spliced forms.  17 
Middle panels: Estrogen starved EREB2.5 cells (E2.5) or AK31:EBNA1/ER-EBNA2 18 
type 1 or type 2 cells (AK31) were pretreated with protein synthesis inhibitors for one 19 
hour (AK31) or 2 hours (E2.5) and the cells were then treated with or without 20 
estrogen for 4 hours in the presence of protein synthesis inhibitors (as in the 21 
microarray experiment in Fig 2). RNA was extracted and analysed by RT-PCR for 22 
CXCR7 mRNA using indicated primer combinations (right panels) Track M is size 23 
markers (100 bp ladder). 24 
 33
B. RT-PCR assay for CXCR7 or ADAMDEC1 mRNA in EREB2.5 cells 7 or 10 days 1 
after transfection with EBNA2 T1 or T2 vector and withdrawal of estrogen as in 2 
Figure 1. CXCR7 primers were those shown in upper panels of Fig 4A. GAPDH 3 
mRNA was also assayed to ensure equal input RNA in the samples.  4 
C. RT-PCR assay for CXCR7 mRNA in a panel of LCLs with primers used in upper 5 
panels of Fig 4A. GAPDH mRNA was also assayed as a control.  6 
 7 
Figure 5 8 
A.   Plasmids expressing shRNA for CXCR7 or p53 as a negative control or the 9 
control empty vector (V) were transfected into EREB2.5 cells and the transfected 10 
cells selected with puromycin. Live cell counts (trypan blue exclusion) are shown at 11 
the indicated times after transfection. CXCR7 RNA was assayed by RT-PCR 7 days  12 
after transfection using the exon 2 primer combination shown in Fig 4A upper panels. 13 
B.   As part A but in LCL3 cells (an LCL infected with B95-8 EBV). Here the 14 
CXCR7 RNA was assayed by RT-PCR 6 days after transfection. 15 
C.   To show that the CXCR7 shRNA plasmid was not non-specifically toxic to cells 16 
and that it did not prevent function of the puromycin resistance gene, the shRNA 17 
plasmids used in parts A and B were transfected into 293 cells and selected with 18 
puromycin. Ctrl sample received a plasmid lacking the puromycin resistance gene. 19 
Live cell counts 8 days after transfection are shown. 20 
 21 
Figure 6  22 
A.  Type 1 and type 2 EBNA2 both repress MYC expression and drive apoptosis in 23 
AK31 BL cells. AK31:EBNA1/ER-EBNA2 T1 and T2 stable cells were induced with 24 
5 μM β-estradiol for 0-72 hours. Extracts from cells were probed with indicated 25 
 34
antibodies.  1 
B.  Analysis of EBNA2 T1 and T2 driven apoptosis in AK31 cells. 2 
AK31:EBNA1/ER-EBNA2 T1 and T2 stable cells induced with 5 μM β-estradiol for 3 
0-72 hours were ethanol fixed and stained with propidium iodide prior to analysis of 4 
DNA content by flow cytometry. Upper panels: DNA content analysis of 5 
AK31:EBNA1/ER-EBNA2 cells following ER-EBNA2 T1 activation demonstrating 6 
transient increase in G0/G1 populations followed by apoptosis at later time-points. 7 
Numbers inserted into histogram profiles denote % subdiploid, G0/G1 , S and G2/M 8 
populations respectively. Lower panels: Bar chart comparing Sub-Diploid and G0/G1 9 
DNA  content for both T1 and T2 ER-EBNA2 stable populations. 10 
C.  Type 1 and type 2 EBNA2 drive mitochondrial/ intrinsic apoptosis in AK31 cells. 11 
AK31:EBNA1/ER-EBNA2 T1 and T2 stable cells were  induced with 5 μM β-12 
estradiol for 0-72 hours and analysed for apoptosis.  The JC-1 assay was performed at 13 
each time point. Upper panel shows example profiles of CCCP-treated positive 14 
control, 0 hour and 72 -/+ activation of T1 ER-EBNA2 stable cells. Bar chart (lower 15 
panel) shows a comparison between EBNA2 T1/T2-driven intrinsic apoptosis or the 16 
percentage of normal (N) cells versus apoptotic (Ap) cells in both cell populations.  17 
DNA  18 
D. DNA laddering analysis was also performed on AK31:EBNA1/ER-EBNA2 T1 or 19 
T2 cells induced with 5 μM β-estradiol for 0-72 hours.  20 
 21 
Figure 7 22 
Daudi BL cells stably transfected with ER-EBNA2 type 1 or type 2 were cultured 23 
with or without estrogen for the indicated times and protein extracts of the cells were 24 
 35
analysed by western blotting for EBNA2 (PE2 antibody), LMP1 (CS1-4 antibody) or 1 
actin as a loading control. 2 
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